Dr. Gayle Kirkpatrick Joins rMark Bio's Advisory Board

CHICAGO, Feb. 8, 2018 /PRNewswire/ -- rMark Bio is pleased to announce that Dr. Gayle Kirkpatrick has joined their Advisory board. The Chicago-based life science SaaS company, which delivers a suite of thought leader engagement applications atop their patented analytics platform, is elated to work with Gayle. Working alongside rMark Bio's leadership team, Gayle is committed to developing plans to expand the adoption of their business intelligence solution for biopharmaceutical and other companies around the world.

Gayle is a business development executive with over 25 years of experience, and has held senior positions at AbbVie/Abbott and Astellas in addition to serving as General Manager at the WiCell Research Institute.  Jason Smith, rMark Bio's CEO, said, "Gayle's wealth of knowledge and expertise in the pharmaceutical industry including technology transfer, licensing, and strategic alliances provides rMark Bio with valuable perspectives as we continue to grow." She joins the other rMark Bio board members, Stuart DePina President of Envestnet|Tamarac and Dr. Christopher Rhodes, VP of Research at MedImmune.

The relationship began after Gayle met rMark Bio founders Jason Smith and Dr. Lev Becker as part of the Chicago Innovation Mentor program.  Gayle was immediately impressed with rMark Bio's leadership and platform.   The company's innovative business intelligence technology provides the biopharmaceutical industry with a significantly enhanced tool pertaining to thought leader identification, engagement, and management.  Ensuring the right people from all sides of the healthcare ecosystem are connected will drive collaboration and knowledge-transfer with the goal of improving healthcare and patients' lives.

"Data and knowledge are evolving at a rapid pace as a result of extensive research and development efforts that are directed at unmet medical needs. To be successful, the biopharmaceutical industry must continually and efficiently access external expertise," said Gayle. "rMark Bio provides a solution to rapidly identify and monitor key thought leaders within clinical areas of strategic importance to it's partners.  Additionally, the rMark Bio platform is highly relevant not only to the biopharmaceutical industry, but also to others such as investment analysts and medical device companies where rapid identification and access to key thought leaders are equally important."

rMark Bio's leadership team is looking forward to working with Gayle and other advisory board members. They will work cohesively to maximize efforts in continuing to produce strategic, technological advances for the pharmaceutical industry. For more information, please visit www.rmarkbio.com.

About rMark Bio
rMark Bio's industry leading AI solution understands the real-time business strategies of R&D, Medical Affairs, Marketing, and Commercial teams to provide field representatives with clear and concise 'next best decisions' that remove inefficiencies and increase ROI for thought leader engagements.

LINKS:
rMark Bio Website: www.rmarkbio.com
Facebook: https://www.facebook.com/rmarkbio
Instagram: https://www.instagram.com/rmarkbio/
Twitter: https://twitter.com/rMarkBio
LinkedIn: https://www.linkedin.com/company/rmark-biogenics/

SOURCE rMark Bio Inc.

Related Links

http://www.rmarkbio.com